WuXi Biologics Partners with Vertex on Trispecific T-Cell Engager for Autoimmune Diseases
核心洞察
WuXi Biologics has signed a license and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T-cell engager (搜索) targeting B-cell mediated autoimmune diseases (搜索).
Vertex gains exclusive global rights to develop and commercialize the preclinical-stage trispecific TCE, with WuXi Biologics receiving upfront payments plus milestone and royalty payments.
The collaboration validates WuXi Biologics' CRDMO model and discovery platforms while providing Vertex with advanced tools to accelerate development of transformative therapies.
WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has entered into a strategic license and research service agreement with Vertex Pharmaceuticals for an innovative trispecific T-cell engager (搜索) (TCE) designed to treat B-cell mediated autoimmune diseases (搜索). The announcement, made on February 2, 2026, represents a significant collaboration in the development of next-generation immunotherapies.
Partnership Terms and Structure
Under the agreement, Vertex Pharmaceuticals will receive exclusive global rights to develop and commercialize the trispecific TCE, which is currently at the preclinical stage. The innovative therapeutic is specifically designed for the treatment of B-cell mediated autoimmune diseases (搜索), representing a novel approach to targeting these conditions.
WuXi Biologics will receive an upfront payment and is eligible for additional compensation through development, regulatory, and sales milestone payments, as well as ongoing royalty payments. Beyond the licensing arrangement, WuXi Biologics will provide Vertex with comprehensive contract research and development services focused on novel next-generation TCEs.
Leadership Perspectives
Dr. Chris Chen, CEO of WuXi Biologics, emphasized the significance of the collaboration, stating, "We are delighted to support Vertex's efforts to bring forward transformative medicines for serious diseases through the study of this TCE, discovered using our state-of-the-art integrated platforms. This collaboration underscores WuXi Biologics' recognition as an industry leader in discovery service solutions and further validates our unique CRDMO model, which enables global partners to develop next-generation modalities."
Dr. Mark Bunnage, Chief Scientific Officer at Vertex, highlighted the strategic value of the partnership: "At Vertex, we are committed to advancing transformative therapies for people with serious diseases. This agreement with WuXi Biologics gives us another important tool to accelerate our efforts to advance new medicines and we're excited to explore the potential of this promising molecule."
WuXi Biologics' Platform Capabilities
The trispecific T-cell engager (搜索) was discovered using WuXi Biologics' integrated platforms, demonstrating the company's advanced capabilities in biologics discovery. As of December 31, 2025, WuXi Biologics supports 945 integrated client projects, including 74 in Phase III clinical trials and 25 in commercial manufacturing stages.
The company operates with over 12,000 skilled employees across multiple global locations, including China, the United States, Ireland, Germany, and Singapore. This international presence enables WuXi Biologics to provide comprehensive biologics discovery, development, and manufacturing solutions from concept to commercialization.
Strategic Implications
This partnership represents a validation of WuXi Biologics' unique CRDMO model and its ability to support global pharmaceutical companies in developing next-generation therapeutic modalities. The collaboration focuses on B-cell mediated autoimmune diseases (搜索), an area of significant unmet medical need where innovative approaches like trispecific T-cell (搜索) engagers could offer new treatment options for patients.